Holen Sie sich die Stockscreener-App
3.86
2.66%
0.10
Handel nachbörslich:
3.82
-0.04
-1.04%
Schlusskurs vom Vortag:
$3.76
Offen:
$3.83
24-Stunden-Volumen:
2.60M
Relative Volume:
2.80
Marktkapitalisierung:
$490.96M
Einnahmen:
$81.36M
Nettoeinkommen (Verlust:
$-142.62M
KGV:
-3.2143
EPS:
-1.2009
Netto-Cashflow:
$-146.97M
1W Leistung:
+2.12%
1M Leistung:
+5.18%
6M Leistung:
-7.21%
1J Leistung:
+199.22%
1-Tages-Spanne:
$3.82
$4.13
1-Wochen-Bereich:
$3.36
$4.13
52-Wochen-Spanne:
$1.225
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.86 | 478.24M | 81.36M | -142.62M | -146.97M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha
ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey
ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart
ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call - Benzinga
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics Reports Narrower Q1 2026 Loss, Beats Estimates - AlphaStreet
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M - Stock Titan
ADC Therapeutics Q1 2026: $0.13/share Loss Beats Estimates — Deep Dive - AlphaStreet
ADC Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ADC Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Reports Q1 2026 Financial Results and Updates – NYSE: ADCT - Minichart
ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ADC Therapeutics Q1 Earnings Call Highlights - MarketBeat
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
ADC Therapeutics : (ADCT 1Q 2026 Earnings) - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued - ChartMill
The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company's cash and cash equivalents totaled 231 million USD. - Bitget
ADC Therapeutics (NYSE:ADCT) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q1 2026 Earnings - Quiver Quantitative
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028 - Stock Titan
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Earnings Scheduled For May 4, 2026 - Benzinga
MSN Money - MSN
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Australia
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - ChartMill
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
ADC Therapeutics schedules May 4 webcast on Q1 results and operations - Stock Titan
Redmile Group (NASDAQ: ADCT) reports 9.9% stake after SPV reorg - Stock Titan
ADC Therapeutics S.A. Investigated by the Portnoy Law Firm - GlobeNewswire
ADC Therapeutics SA ($ADCT) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, equity plan and capital changes at ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics (NASDAQ: ADCT) adds SILV Fund as selling shareholder - Stock Titan
ADC Therapeutics (NYSE:ADCT) Shares Up 11.8%Still a Buy? - MarketBeat
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - ADVFN
ADC Therapeutics (NYSE: ADCT) to hold virtual AGM June 1; votes on capital and pay - Stock Titan
Aug Spikes: Can ADC Therapeutics SA continue delivering strong returns2026 Key Lessons & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ADC Therapeutics SA $ADCT Stock Holdings Raised by JPMorgan Chase & Co. - MarketBeat
ADCT.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):